Schizophrenia therapy: Beyond atypical antipsychotics

Nature Reviews Drug Discovery

Volumn 7, Issue 6, 2008, Pages 471-472

  Snyder, Eric M ^a   Murphy, Melanie R ^a  

^a Mehta Partners Global BioPharmaceutical Investments   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADX 63365; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE; DOPAMINE 2 RECEPTOR; GLUTAMIC ACID; HALOPERIDOL; LY 2140023; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR AGONIST; NEUROLEPTIC AGENT; OLANZAPINE; PRIMAVANSERIN; QUETIAPINE; RISPERIDONE; SEROTONIN 2 AGONIST;

ARTICLE; CLINICAL TRIAL; COGNITION; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LOW DRUG DOSE; MOTOR DYSFUNCTION; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SIGNAL TRANSDUCTION; WEIGHT GAIN; WEIGHT REDUCTION;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA;

EID: 44449166578     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2571     Document Type: Article

References (5)

1. Lieberman, J. A. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209-1223 (2005).
2. Patil, S. et al. Activation of mCluR2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial. Nature Med. 13, 1102-1107 (2007).
3. Sesasck, S. et al. Anatomical substrates for glutamate-dopamine interactions: Evidence for specificity of connections and extrasynaptic actions. Ann. NY Acad. Sci. 1003, 36-52 (2003).
4. Moghaddam, B. Bringing order to the glutamate chaos in schizophrenia. Neuron 40, 881-884 (2003).
5. Gonzalez-Maeso, J. et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452, 93-97 (2008).